Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i> -mutant solid tumors

Alison M. Schram, John J. Park, Antoine Italiano, Shigehisa Kitano, Ye Guo, Jin Li, Philippe L. Bedard, Cedric van Marcke, Ryo Ko, Lukas Lunger, Daniel M. Klotz, Jo Hussain, Daniela Maier, Damijan Erzen, David Planchard, Hans Prenen, Timothy D. Clay, Joon O. Park, Hyung-Don Kim, Alberto Hernando-Calvo, Yuta Maruki, Mariano Ponz-Sarvise, Ecaterina Dumbrava

Open source

DOI: 10.1080/14796694.2026.2637740
Published: 2026-03-04
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2637740,
  title = {Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or
                    <i>HER2</i>
                    -mutant solid tumors},
  author = {Alison M. Schram and John J. Park and Antoine Italiano and Shigehisa Kitano and Ye Guo and Jin Li and Philippe L. Bedard and Cedric van Marcke and Ryo Ko and Lukas Lunger and Daniel M. Klotz and Jo Hussain and Daniela Maier and Damijan Erzen and David Planchard and Hans Prenen and Timothy D. Clay and Joon O. Park and Hyung-Don Kim and Alberto Hernando-Calvo and Yuta Maruki and Mariano Ponz-Sarvise and Ecaterina Dumbrava},
  year = {2026},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2026.2637740},
  url = {https://doi.org/10.1080/14796694.2026.2637740}
}

RIS

TY  - JOUR
TI  - Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or
                    <i>HER2</i>
                    -mutant solid tumors
AU  - Alison M. Schram
AU  - John J. Park
AU  - Antoine Italiano
AU  - Shigehisa Kitano
AU  - Ye Guo
AU  - Jin Li
AU  - Philippe L. Bedard
AU  - Cedric van Marcke
AU  - Ryo Ko
AU  - Lukas Lunger
AU  - Daniel M. Klotz
AU  - Jo Hussain
AU  - Daniela Maier
AU  - Damijan Erzen
AU  - David Planchard
AU  - Hans Prenen
AU  - Timothy D. Clay
AU  - Joon O. Park
AU  - Hyung-Don Kim
AU  - Alberto Hernando-Calvo
AU  - Yuta Maruki
AU  - Mariano Ponz-Sarvise
AU  - Ecaterina Dumbrava
PY  - 2026
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2637740
UR  - https://doi.org/10.1080/14796694.2026.2637740
ER  -

APA

Schram, A. M., Park, J. J., Italiano, A., Kitano, S., Guo, Y., Li, J., Bedard, P. L., Marcke, C. V., Ko, R., Lunger, L., Klotz, D. M., Hussain, J., Maier, D., Erzen, D., Planchard, D., Prenen, H., Clay, T. D., Park, J. O., Kim, H., Hernando-Calvo, A., Maruki, Y., Ponz-Sarvise, M., & Dumbrava, E. (2026). Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i> -mutant solid tumors. Future Oncology. https://doi.org/10.1080/14796694.2026.2637740

Source records

crossref · retrieved 2026-09-26T05:52:40.515Z